Systems Biology Opens the Blackest Boxes
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
On June 12, NIH’s National Center for Advancing Translational Sciences (NCATS) will disclose its list of molecules for repurposing under a joint agency-industry pilot program. The initiative, Discovering New Therapeutic Uses for Existing Molecules, was announced last month. Pfizer, AstraZeneca, and Eli Lilly have agreed to allow researchers to study some of their shelved compounds, in hopes of advancing the understanding of various disease mechanism as well as finding new indications. Additional pharma companies may join, increasing the number of shelved compounds available for study.